Leading Liquid Biopsy Company, Exosome Diagnostics, Appoints Daniel Zabrowski As Board Member

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Exosome Diagnostics, the developer of a leading liquid biopsy platform that enables non-invasive diagnosis of disease states, potentially obviating the need for tissue biopsy, has announced the appointment of Dan Zabrowski PhD, as a member of its Board of Directors.

Suggested Articles

A TGen-led research team found that increased activity of the gene AEBP1 drives severe liver fibrosis in nonalcoholic steatohepatitis.

Days after announcing its R&D chief was stepping down, Gilead announced it will be buying a few of Novartis’ unwanted early-stage infection assets.

Mallinckrodt is teaming up with Silence Therapeutics to develop an RNAi program aimed at a group of proteins that play a part in promoting inflammation.